IRIS UniCatt

Pugliese, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.491
AS - Asia 2.816
EU - Europa 2.344
SA - Sud America 681
AF - Africa 94
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
OC - Oceania 1
Totale 9.431
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.375
SG - Singapore 1.320
DE - Germania 612
CN - Cina 594
BR - Brasile 553
SE - Svezia 387
IT - Italia 322
VN - Vietnam 297
FR - Francia 290
GB - Regno Unito 158
IN - India 124
IE - Irlanda 116
FI - Finlandia 102
UA - Ucraina 97
ID - Indonesia 94
JP - Giappone 78
CA - Canada 67
RU - Federazione Russa 57
AR - Argentina 55
PL - Polonia 49
HK - Hong Kong 46
BD - Bangladesh 42
KR - Corea 41
TR - Turchia 40
ES - Italia 33
MX - Messico 33
NL - Olanda 29
IQ - Iraq 28
AT - Austria 25
ZA - Sudafrica 25
EC - Ecuador 22
CO - Colombia 17
BE - Belgio 15
MA - Marocco 13
SA - Arabia Saudita 13
CI - Costa d'Avorio 12
IR - Iran 11
PK - Pakistan 11
UZ - Uzbekistan 11
CZ - Repubblica Ceca 10
IL - Israele 10
PH - Filippine 10
VE - Venezuela 10
EG - Egitto 9
JO - Giordania 9
KE - Kenya 8
UY - Uruguay 8
DZ - Algeria 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
JM - Giamaica 6
PE - Perù 6
HU - Ungheria 5
AL - Albania 4
BG - Bulgaria 4
LT - Lituania 4
NP - Nepal 4
AZ - Azerbaigian 3
CL - Cile 3
ET - Etiopia 3
HN - Honduras 3
KZ - Kazakistan 3
LV - Lettonia 3
OM - Oman 3
PT - Portogallo 3
PY - Paraguay 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CR - Costa Rica 2
GA - Gabon 2
HR - Croazia 2
KG - Kirghizistan 2
LB - Libano 2
MM - Myanmar 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AQ - Antartide 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
ML - Mali 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
Totale 9.421
Salva come PNG Salva come JPEG
Città #
Singapore 752
Chandler 451
San Jose 372
Ashburn 352
Beijing 164
New York 152
Los Angeles 119
Dublin 112
Ho Chi Minh City 95
Hefei 86
The Dalles 82
Lauterbourg 81
Jacksonville 78
Jakarta 75
Tokyo 71
Hanoi 65
Munich 65
Frankfurt am Main 61
San Mateo 61
Rome 57
Dearborn 54
Milan 53
São Paulo 47
Boston 45
Ann Arbor 44
Cattolica 43
Hong Kong 41
Council Bluffs 40
Helsinki 40
Seoul 39
Houston 36
Warsaw 35
Princeton 34
Wilmington 33
Moscow 31
Nürnberg 30
Nanjing 29
Chicago 28
Marseille 28
Paris 28
Hyderabad 27
Dallas 26
Montreal 25
Bremen 23
Kent 23
Turku 23
London 22
Santa Clara 22
Denver 21
Nuremberg 21
Seattle 21
Lappeenranta 20
Orem 20
St Louis 20
Boardman 19
Da Nang 19
Stockholm 19
Toronto 19
Brooklyn 18
Chennai 18
Düsseldorf 18
Lawrence 17
Buffalo 16
Johannesburg 16
Lancaster 16
Belo Horizonte 15
Brussels 15
Fairfield 15
Amsterdam 14
Baghdad 14
Detroit 14
Haiphong 14
Redwood City 14
Rio de Janeiro 13
Abidjan 12
Atlanta 12
Falkenstein 12
Izmir 12
North Bergen 12
Poplar 12
Shenyang 12
Mexico City 11
Vienna 11
Augusta 10
Brasília 10
Cagliari 10
Curitiba 10
Elk Grove Village 10
Leawood 10
Manchester 10
Mumbai 10
Nanchang 10
San Francisco 10
Shanghai 10
Woodbridge 10
Amman 9
Ankara 9
Dhaka 9
Phoenix 9
Quito 9
Totale 5.017
Salva come PNG Salva come JPEG
Nome #
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 219
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 209
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 197
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 190
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 189
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 188
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 171
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 169
Ileal Crohn's disease: CEUS determination of activity 161
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 157
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 155
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 152
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 151
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 144
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 137
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 135
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 133
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 131
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 130
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 129
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 128
Management of perianal fistulas in Crohn's disease: an up-to-date review 127
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 127
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 126
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 123
Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases 120
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 119
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 118
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 117
Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis 113
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 113
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis 113
Radiomics could predict surgery at 10 years in Crohn's disease 112
Crohn's Disease: Radiological Answers to Clinical Questions and Review of the Literature 112
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 111
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 110
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 107
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 107
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 106
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 105
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 105
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 104
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 104
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 101
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 101
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 99
Frontiers in drug research and development for inflammatory bowel disease 99
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 99
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 98
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report 98
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 97
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 97
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 94
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 94
Clinical, Radiological, and Surgical Risk Factors for Endoscopic Anastomotic Recurrence Following Surgery in Crohn's Disease 93
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 91
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 91
Adalimumab in active ulcerative colitis: a "real-life" observational study 91
Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study 90
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab 89
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 89
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study 88
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 88
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 88
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 87
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 86
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 85
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 84
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 84
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 83
PragmaticTrial Design to Compare Real-world Effectiveness of DifferentTreatments for Inflammatory Bowel Diseases:The PRACTICE-IBD European Consensus 82
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 79
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study 78
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 78
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 77
Diet and nutrients in gastrointestinal chronic diseases 77
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 75
Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study 74
Effectiveness of autologous emulsified stromal vascular fraction tissue injection for the treatment of complex perianal fistulas in inflammatory bowel diseases patients: a pilot study 74
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 73
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 72
Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease 71
The inflammatory bowel disease care manager: Italian state of the art 69
Reply to managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers 65
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 63
Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report 58
Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study 36
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference 29
Totale 9.588
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.264
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.264
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202183 0 0 0 0 0 0 0 0 0 10 62 11
2021/2022458 37 19 8 70 8 10 10 65 9 25 90 107
2022/20231.127 148 147 78 182 71 130 54 103 143 15 36 20
2023/2024767 18 161 30 72 23 126 45 48 41 39 72 92
2024/20251.734 20 43 137 30 129 65 133 84 207 217 365 304
2025/20264.274 687 236 331 631 752 208 670 202 269 288 0 0
Totale 9.588